Disease-modifying drugs for systemic sclerosis: Why have we not found them yet?

Expert Review of Clinical Immunology

Volumn 7, Issue 4, 2011, Pages 399-401

  Derk, Chris T ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

disease modifying; drug design; drugs; scleroderma; systemic sclerosis; therapy

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOGLOBULIN; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EARLY DIAGNOSIS; HUMAN; IMMUNOMODULATION; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS, PHARMACOLOGICAL; DRUG DISCOVERY; HUMANS; IMMUNOMODULATION; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79960905563     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.29     Document Type: Review

References (11)

1. Jimenez SA, Derk CT. Following the molecular pathways toward a better understanding of the pathogenesis of systemic sclerosis. Ann Intern. Med 140(1), 37-50 (2004) (Pubitemid 38055920)
2. Carwile LeRoy E, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis J. Rheumatol. 15(2), 202-205 (1988) (Pubitemid 18073738)
3. White B, Bauer EA, Goldsmith LA et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. The American College of Rheumatology Committee on design and outcomes in clinical trials in systemic sclerosis. Arthritis Rheum. 38(3), 351-360 (1995)
4. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J. Rheumatol. 35(4), 364-372 (1996)
5. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 48(12), 1595-1599 (2009)
6. Nihtyanova SI, Brough GM, Black CM, Denton CP Mycophenolate mofetil in diffuse cutaneous systemic sclerosis -a retrospective analysis. Rheumatology 46(3), 442-445 (2007) (Pubitemid 46344656)
7. Tashkin DP, Elashoff R, Clements PJ et al.; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J. Med 354(25), 2655-2666 (2006)
8. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54(12), 3962-3970 (2006) (Pubitemid 44955900)
9. Clements PJ, Furst DE, Wong WK et al. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 42(6), 1194-1203 (1999) (Pubitemid 29268956)
10. Seibold JR, Korn JH, Simms R et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern. Med 132(11), 871-879 (2000) (Pubitemid 30346849)
11. Denton CP, Merkel PA, Furst DE et al.; Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56(1), 323-333 (2007) (Pubitemid 46106206)